A cost-utility analysis of ingenol mebutate gel for the treatment of actinic keratosis: a Scottish perspective
- 390 Downloads
Actinic keratosis (AK) is a UV-induced, pre-malignant skin condition that is common in adults over 60 years of age with fair skin in Scotland. The most commonly prescribed first-line treatment for AK in Scotland is currently diclofenac gel (3 %). Ingenol mebutate gel is a recently developed topical therapy available in two strengths for the treatment of AK lesions on the face and scalp (150 mcg/g once daily for 3 consecutive days) or trunk and extremities (500 mcg/g once daily for 2 consecutive days).
To compare the cost-effectiveness of two strengths of ingenol mebutate gel developed to treat AK lesions on the face and scalp (150 mcg/g once daily for 3 consecutive days) or trunk and extremities (500 mcg/g once daily for 2 consecutive days) with other first-line AK therapies including diclofenac gel, 5-FU, 5-FU/salicylic acid, and cryotherapy for the first-line treatment of AK in adult patients, from the perspective of the National Health Service (NHS) in Scotland.
A cost-utility analysis was conducted using a decision-tree approach to calculate the costs and benefits of different treatment strategies for AK on the face and scalp or trunk and limbs over a 12-month time horizon. Data on the relative efficacy of treatments were obtained from a systematic literature review and meta-analysis. Utility scores and resource-use data were obtained from published sources.
Over 12 months, ingenol mebutate 150 mcg/g gel and 500 mcg/g gel were cost-effective compared with the most commonly used topical therapy in Scotland, diclofenac (3 %) gel, at a willingness-to-pay threshold of £20,000 per QALY, with a minimal additional cost of £43 and £105, respectively per QALY gained.
Ingenol mebutate gel is a cost-effective therapy for the first-line treatment of AK from a Scottish NHS perspective.
KeywordsIngenol mebutate gel Actinic keratosis Cost-effectiveness ICER
This study was funded by LEO Pharma.
- 2.Primary Care Dermatology Society: Actinic keratosis (syn. solar keratosis). http://www.pcds.org.uk/image-atlas/a-z-of-diagnosis/50-image-atlas-detailed-articles/73-actinic-keratosis (2010)
- 6.Cancer Research UK: Skin cancer mortality statistics. http://www.cancerresearchuk.org/cancer-info/cancerstats/types/skin/mortality/#source14 (2013). Accessed July 2013
- 7.Criscione, V.D., Weinstock, M.A., Naylor, M.F., Luque, C., Eide, M.J., Bingham, S.F.: Actinic keratoses: natural history and risk of malignant transformation in the Veterans affairs topical tretinoin chemoprevention trial. Cancer 115(11), 2523–2530 (2009). doi: 10.1002/cncr.24284 CrossRefPubMedGoogle Scholar
- 8.Einspahr, J.G., Stratton, S.P., Bowden, G.T., Alberts, D.S.: Chemoprevention of human skin cancer. Crit Rev Oncol Hematol 41(3):269–285 (2002). pii: S1040842801001858Google Scholar
- 10.Scottish Medicines Consortium: Imiquimod 5% cream (Aldara®). Meda Pharmaceuticals. SMC No. (385/07). http://www.scottishmedicines.org.uk/SMC_Advice/Advice/385_07_imiquimod_cream__Aldara_/imiquimod_cream__Aldara_ (2008). Accessed July 2013
- 11.Scottish Medicines Consortium (SMC): Methyl aminolevulinate 160 mg/g cream (Metvix®). Galderma Ltd. SMC No. (50/03) Available at: http://www.scottishmedicines.org.uk/SMC_Advice/Advice/Methyl_amonolevulinate__Metvix_cream__174___for_actinic_keratoses/Methyl_aminolevulinate__Metvix_cream__ (2003). Accessed July 2013
- 12.Scottish Medicines Consortium: 5-aminolaevulinic acid (as hydrochloride), 78 mg/g, gel (Ameluz®). SMC No. (811/12) (2012)Google Scholar
- 13.NHS Scotland, S.D.S.: Solar (Actinic) keratoses and Bowen’s disease. Dermatology referral and management pathway (2010)Google Scholar
- 14.eMC: Summary of Product Characteristics: Actikerall 5 mg/g + 100 mg/g Cutaneous Solution. http://www.medicines.org.uk/EMC/medicine/24614/SPC/Actikerall+5mg+g+%2B+100mg+g+Cutaneous+Solution/ (2011). Accessed July 2013
- 15.eMC: Summary of Product Characteristics: Solaraze. http://www.medicines.org.uk/emc/medicine/21229) (2012). Accessed July 2013
- 16.eMC: Summary of Product Characteristics: Efudix Cream. http://www.medicines.org.uk/emc/medicine/6219/SPC/Efudix+Cream/ (2011). Accessed July 2013
- 19.Jeffes, E.W., McCullough, J.L., Weinstein, G.D., Fergin, P.E., Nelson, J.S., Shull, T.F., Simpson, K.R., Bukaty, L.M., Hoffman, W.L., Fong, N.L.: Photodynamic therapy of actinic keratosis with topical 5-aminolevulinic acid. A pilot dose-ranging study. Arch. Dermatol. 133(6), 727–732 (1997)CrossRefPubMedGoogle Scholar
- 20.Taub, A.F., Garretson, C.B.: A randomized, blinded, bilateral intraindividual, vehicle-controlled trial of the use of photodynamic therapy with 5-aminolevulinic acid and blue light for the treatment of actinic keratoses of the upper extremities. J. Drugs Dermatol. 10(9), 1049–1056 (2011)PubMedGoogle Scholar
- 22.Ulrich, M., Völker-Call, M., Lange-Asschenfeldt, S., Röwert-Huber, J., Østerdal, M.L., Skak, K., Skov, T., Stockfleth, E.: Biological effects of ingenol mebutate gel, 0.05%, for the treatment of actinic keratosis as assessed by reflectance confocal microscopy. Poster presented at American Academy of Dermatology Summer Academy Meeting Aug 15–19 2012, Boston, MA. USA. (2) (2012)Google Scholar
- 25.ISD Scotland: Prescription Cost Analysis for financial year 2011/12. http://www.isdscotland.org/Health-Topics/Prescribing-and-Medicines/Publications/data-tables.asp (2012)
- 26.Dias, S., Welton, N.J., Sutton, A.J., Ades, A.E.: NICE DSU technical support document 5: Evidence synthesis in the baseline natural history model. http://www.nicedsu.org.uk/TSD5%20Baseline.final%20report.08.05.12.pdf (2011)
- 27.Krawtchenko, N., Roewert-Huber, J., Ulrich, M., Mann, I., Sterry, W., Stockfleth, E.: A randomised study of topical 5% imiquimod vs. topical 5-fluorouracil vs. cryosurgery in immunocompetent patients with actinic keratoses: a comparison of clinical and histological outcomes including 1-year follow-up. Br. J. Dermatol. 157(Suppl 2), 34–40 (2007)CrossRefPubMedGoogle Scholar
- 28.eMC: Summary of Product Characteristics: Picato 150 mcg/g Gel. http://www.medicines.org.uk/emc/medicine/27246/SPC/Picato+150+mcg+g+Gel/ (2012). Accessed July 2013
- 31.Chen, S.C., Bayoumi, A.M., Soon, S.L., Aftergut, K., Cruz, P., Sexton, S.A., McCall, C.O., Goldstein, M.K.: A catalog of dermatology utilities: a measure of the burden of skin diseases. J Investig Dermatol Symp Proc 9(2), 160–168 (2004). doi: 10.1046/j.1087-0024.2003.09112.x CrossRefPubMedGoogle Scholar
- 32.MIMS: Monthly Index of Medical Specialities (MIMS). Haymarket Medical Media, London (July 2012)Google Scholar
- 33.Thomas, K.S., Keogh-Brown, M.R., Chalmers, J.R., Fordham, R.J., Holland, R.C., Armstrong, S.J., Bachmann, M.O., Howe, A.H., Rodgers, S., Avery, A.J., Harvey, I., Williams, H.C.: Effectiveness and cost-effectiveness of salicylic acid and cryotherapy for cutaneous warts. An economic decision model. Health Technol Assess 10(25), iii, ix-87 (2006). doi:02-12-03 [pii]Google Scholar
- 34.Curtis, L.: Unit Costs of Health and Social Care 2011. Personal Social Services Research Unit, Canterbury (2011)Google Scholar
- 35.ISD Scotland: Acute medical costs R044X: Specialty group costs—consultant outpatients (2011)Google Scholar
- 38.Scottish Medicines Consortium: ingenol mebutate, 150 & 500micrograms/g, gel (Picato®) SMC No. (851/13). http://www.scottishmedicines.org.uk/files/advice/ingenol_mebutate_gel_Picato_FINAL_FEBRUARY_2013_amended_04.03.13_for_website.pdf (2013). Accessed Aug 2013
- 39.Scottish Medicines Consortium: Guidance to manufacturers for completion of New Product Assessment Form (NPAF). (2012)Google Scholar
- 40.Jorizzo, J., Dinehart, S., Matheson, R., Moore, J.K., Ling, M., Fox, T.L., McRae, S., Fielder, S., Lee, J.H.: Vehicle-controlled, double-blind, randomized study of imiquimod 5% cream applied 3 days per week in one or two courses of treatment for actinic keratoses on the head. J. Am. Acad. Dermatol. 57(2), 265–268 (2007)CrossRefPubMedGoogle Scholar
- 43.European Dermatology Forum: Guideline on Actinic Keratoses (update) (2011)Google Scholar